Nuvectis Pharma (NVCT) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 12, 2025, with virtual participation available for shareholders.

• Shareholders are encouraged to review proxy materials and vote by June 11, 2025.

Voting matters and shareholder proposals

• Election of James F. Oliviero as director is on the ballot, with board recommendation to vote in favor.

• Ratification of Kesselman & Kesselman (PwC member) as independent auditor for fiscal year ending December 31, 2025, is proposed, with board support.

• Other business may be transacted as appropriate during the meeting or any adjournment.

Board of directors and corporate governance

• Board recommends voting in favor of the director nominee and auditor ratification.